[Direct relationship to need for individualization]:Conference call with the NASEM Committee on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Replacement Therapy and Daved Rosensweet M.D. Dr Rosensweet’s responses to questions from the NASEM Committee on 8/22/19:Questions 2 & 3:
[questions to Dr Rosensweet from the. NAAEM Committee:] “Formulations:In your email, you mention that the customization for topical hormones musttake into consideration the ratios of E3 to E2. Could you please submit data that outlines the most commonly formulated ratios of E3 to E2 and E2 to E1 in cBHRT preparations? Could you also please …
